Literature DB >> 30642824

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

Khashayar Esfahani1, Nicholas Meti2, Wilson H Miller2, Marie Hudson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30642824      PMCID： PMC6333545          DOI： 10.1503/cmaj.180870

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  37 in total

1.  Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

Authors:  Khashayar Esfahani; Wilson H Miller
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

2.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Authors:  Noha Abdel-Wahab; Mohsin Shah; Maria A Lopez-Olivo; Maria E Suarez-Almazor
Journal:  Ann Intern Med       Date:  2018-01-02       Impact factor: 25.391

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

5.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.

Authors:  J C Osorio; A Ni; J E Chaft; R Pollina; M K Kasler; D Stephens; C Rodriguez; L Cambridge; H Rizvi; J D Wolchok; T Merghoub; C M Rudin; S Fish; M D Hellmann
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

6.  Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.

Authors:  Rakiba Belkhir; Sébastien Le Burel; Laetitia Dunogeant; Aurélien Marabelle; Antoine Hollebecque; Benjamin Besse; Alexandra Leary; Anne-Laure Voisin; Clémence Pontoizeau; Laetitia Coutte; Edouard Pertuiset; Gaël Mouterde; Olivier Fain; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2017-06-09       Impact factor: 19.103

7.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

8.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

Authors:  A M Menzies; D B Johnson; S Ramanujam; V G Atkinson; A N M Wong; J J Park; J L McQuade; A N Shoushtari; K K Tsai; Z Eroglu; O Klein; J C Hassel; J A Sosman; A Guminski; R J Sullivan; A Ribas; M S Carlino; M A Davies; S K Sandhu; G V Long
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

9.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.

Authors:  Krista Dubin; Margaret K Callahan; Boyu Ren; Raya Khanin; Agnes Viale; Lilan Ling; Daniel No; Asia Gobourne; Eric Littmann; Curtis Huttenhower; Eric G Pamer; Jedd D Wolchok
Journal:  Nat Commun       Date:  2016-02-02       Impact factor: 14.919

10.  Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.

Authors:  Adam Diehl; Mark Yarchoan; Alex Hopkins; Elizabeth Jaffee; Stuart A Grossman
Journal:  Oncotarget       Date:  2017-12-14
View more
  10 in total

1.  Enteritis with immune checkpoint inhibitor use.

Authors:  David Sanders; Douglas Webber; Nazira Chatur
Journal:  CMAJ       Date:  2019-10-07       Impact factor: 8.262

Review 2.  Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

Authors:  J Claveau; J Archambault; D S Ernst; C Giacomantonio; J J Limacher; C Murray; F Parent; D Zloty
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

Review 3.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

4.  Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.

Authors:  Yi-Hui Li; Yang Zhou; Yuan-Yuan Liu; Guang-Ju Zhang; Lei Xiao; Na Li; Hai-Feng Qin; Jian-Gong Wang; Li Zhang
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

5.  A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen.

Authors:  Jun Yin; Meng Wen; Jun Cheng; Lifen Hu; Li Yang; Xiao Chang; Zhongsong Zhou; Hongbin Li; Yan Liu; Jiabin Li
Journal:  Front Med (Lausanne)       Date:  2022-02-21

6.  Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.

Authors:  Christopher Ma; Rish K Pai; David F Schaeffer; Jonathan Krell; Leonardo Guizzetti; Stefanie C McFarlane; John K MacDonald; Won-Tak Choi; Roger M Feakins; Richard Kirsch; Gregory Y Lauwers; Reetesh K Pai; Christophe Rosty; Amitabh Srivastava; Joanna C Walsh; Brian G Feagan; Vipul Jairath
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

7.  Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists.

Authors:  Irena Druce; Karine Tawagi; Julie L V Shaw; Andrea Ibrahim; Heather Lochnan; Michael Ong
Journal:  Curr Oncol       Date:  2022-07-02       Impact factor: 3.109

Review 8.  Adverse Renal Effects of Anticancer Immunotherapy: A Review.

Authors:  Maciej Borówka; Stanisław Łącki-Zynzeling; Michał Nicze; Sylwia Kozak; Jerzy Chudek
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 9.  Thyroid-related adverse events induced by immune checkpoint inhibitors.

Authors:  Alexandra Chera; Andreea Lucia Stancu; Octavian Bucur
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

10.  Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Authors:  Khashayar Esfahani; Tho-Alfakar Al-Aubodah; Pamela Thebault; Réjean Lapointe; Marie Hudson; Nathalie A Johnson; Dana Baran; Najwa Bhulaiga; Tomoko Takano; Jean-François Cailhier; Ciriaco A Piccirillo; Wilson H Miller
Journal:  Nat Commun       Date:  2019-10-17       Impact factor: 14.919
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.